Well from the sound of it CF33 makes the old scale redundent.
I think it is far from clear that her-vaxx isnt worth the trouble. They are in negotiations. The market is slow and having $150m in cash they dont need to hurry. I heard in one of these threads that the most advanced trial on her-vaxx had only 19 patients. More data is need to get deals made.
Ann: Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration, page-159
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.001(0.94%) |
Mkt cap ! $404.2M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.5¢ | 5.3¢ | $105.2K | 1.953M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 867376 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 185661 | 14 |
View Market Depth
| Last trade - 12.45pm 01/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |